Treatment of central precocious puberty with triptorelin 11.25 mg depot formulation.

Martínez-Aguayo A, Hernández MI, Beas F, Iñiguez G, Avila A, Sovino H, Bravo E, Cassorla F

Journal of pediatric endocrinology & metabolism : JPEM1 Aug 2006Cited by 19 (Europe PMC)

PMID16995580DOI10.1515/jpem.2006.19.8.963PepBankPUB-16995580

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanNon-randomized trialEfficacy outcome
In children with central precocious puberty, triptorelin significantly reduced basal LH from baseline to 3 months.
In plain wordsIn children with central precocious puberty, triptorelin reduced basal LH compared with baseline after 3 months.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseBasal LH
Study
n = 20
Comparator
Baseline
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
11.25 mg every 90 days · 3 monthsAs given in this study (human).
Source sentences
Summary
The basal and GnRH-stimulated serum levels of LH and FSH decreased significantly from baseline to 3 months of therapy (p <0.0001).
2 context sentences(design, population, supporting numbers)
Summary · context
The aim of our study was to evaluate the efficacy of triptorelin 11.25 mg administered every 90 days to suppress gonadotropin and sex steroid secretion and pubertal signs in children with CPP during 2 years of treatment.
Summary · context
We studied 20 patients (19 girls and 1 boy), with a median age at entry into the study of 7.5 +/- 0.2 years for girls, and 9 years for the boy.
Report a problemFND-1699558001
02HumanNon-randomized trialEfficacy outcome
In children with central precocious puberty, triptorelin significantly reduced GnRH-stimulated LH from baseline to 3 months.
In plain wordsIn children with central precocious puberty, triptorelin reduced stimulated LH compared with baseline after 3 months.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseGnRH-stimulated LH
Study
n = 20
Comparator
Baseline
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
11.25 mg every 90 days · 3 monthsAs given in this study (human).
Source sentences
Summary
The basal and GnRH-stimulated serum levels of LH and FSH decreased significantly from baseline to 3 months of therapy (p <0.0001).
2 context sentences(design, population, supporting numbers)
Summary · context
The aim of our study was to evaluate the efficacy of triptorelin 11.25 mg administered every 90 days to suppress gonadotropin and sex steroid secretion and pubertal signs in children with CPP during 2 years of treatment.
Summary · context
We studied 20 patients (19 girls and 1 boy), with a median age at entry into the study of 7.5 +/- 0.2 years for girls, and 9 years for the boy.
Report a problemFND-1699558002
03HumanNon-randomized trialEfficacy outcome
In children with central precocious puberty, triptorelin significantly reduced basal FSH from baseline to 3 months.
In plain wordsIn children with central precocious puberty, triptorelin reduced basal FSH compared with baseline after 3 months.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseBasal FSH
Study
n = 20
Comparator
Baseline
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
11.25 mg every 90 days · 3 monthsAs given in this study (human).
Source sentences
Summary
The basal and GnRH-stimulated serum levels of LH and FSH decreased significantly from baseline to 3 months of therapy (p <0.0001).
2 context sentences(design, population, supporting numbers)
Summary · context
The aim of our study was to evaluate the efficacy of triptorelin 11.25 mg administered every 90 days to suppress gonadotropin and sex steroid secretion and pubertal signs in children with CPP during 2 years of treatment.
Summary · context
We studied 20 patients (19 girls and 1 boy), with a median age at entry into the study of 7.5 +/- 0.2 years for girls, and 9 years for the boy.
Report a problemFND-1699558003
04HumanNon-randomized trialEfficacy outcome
In children with central precocious puberty, triptorelin significantly reduced GnRH-stimulated FSH from baseline to 3 months.
In plain wordsIn children with central precocious puberty, triptorelin reduced stimulated FSH compared with baseline after 3 months.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseGnRH-stimulated FSH
Study
n = 20
Comparator
Baseline
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
11.25 mg every 90 days · 3 monthsAs given in this study (human).
Source sentences
Summary
The basal and GnRH-stimulated serum levels of LH and FSH decreased significantly from baseline to 3 months of therapy (p <0.0001).
2 context sentences(design, population, supporting numbers)
Summary · context
The aim of our study was to evaluate the efficacy of triptorelin 11.25 mg administered every 90 days to suppress gonadotropin and sex steroid secretion and pubertal signs in children with CPP during 2 years of treatment.
Summary · context
We studied 20 patients (19 girls and 1 boy), with a median age at entry into the study of 7.5 +/- 0.2 years for girls, and 9 years for the boy.
Report a problemFND-1699558004
05HumanNon-randomized trialEfficacy outcome
In children with central precocious puberty receiving triptorelin, all patients had a GnRH-stimulated peak below 3 mIU/ml between 6 and 24 months.
In plain wordsIn children receiving triptorelin for precocious puberty, all stimulated peaks stayed below 3 mIU/ml between 6 and 24 months.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseGnRH-stimulated peak suppression
Study
n = 20
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
11.25 mg every 90 days · 6 to 24 monthsAs given in this study (human).
Measurements
GnRH-stimulated peak
< 3 mIU/ml
all patients between 6 and 24 months
Source sentences
Summary
All patients had a GnRH-stimulated peak below 3 mIU/ml between 6 and 24 months of treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
The aim of our study was to evaluate the efficacy of triptorelin 11.25 mg administered every 90 days to suppress gonadotropin and sex steroid secretion and pubertal signs in children with CPP during 2 years of treatment.
Summary · context
We studied 20 patients (19 girls and 1 boy), with a median age at entry into the study of 7.5 +/- 0.2 years for girls, and 9 years for the boy.
Report a problemFND-1699558005
06HumanNon-randomized trialEfficacy outcome
In children treated with triptorelin for central precocious puberty, the pituitary-gonadal axis recovered adequately after treatment stopped.
In plain wordsIn children treated with triptorelin for precocious puberty, the pituitary-gonadal axis recovered after treatment stopped.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicablePituitary-gonadal axis recovery
Study
n = 20
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
11.25 mg every 90 days · 2 yearsAs given in this study (human).
Source sentences
Summary
The pituitary-gonadal axis recovered adequately after discontinuation of therapy.
2 context sentences(design, population, supporting numbers)
Summary · context
The aim of our study was to evaluate the efficacy of triptorelin 11.25 mg administered every 90 days to suppress gonadotropin and sex steroid secretion and pubertal signs in children with CPP during 2 years of treatment.
Summary · context
We studied 20 patients (19 girls and 1 boy), with a median age at entry into the study of 7.5 +/- 0.2 years for girls, and 9 years for the boy.
Report a problemFND-1699558006

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT01467882

Efficacy, Safety, and Pharmacokinetics (PK) of Triptorelin 6-month Formulation in Patients With Central Precocious Puberty

Debiopharm International SAn = 44Apr 2012 to Jul 2014

Central Precocious Puberty

Trial page ClinicalTrials.govUpdated 28 Jul 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.